Momentum is building for $DARE!
CEO Sabrina Martucci Johnson highlighted growing demand for DARE to PLAY™ Sildenafil Cream, with prescriptions written across 48 states and Washington, D.C. ahead of dispensing.
Read the Q3 2026 update: https://t.co/nQpZLpbQpr
In the latest CEO Corner, Sabrina Martucci Johnson, Founder, President and CEO of $DARE, discusses numerous potential value drivers expected to power the Company’s next phase of growth and commercial success.
🔗: https://t.co/4xIYdmFIdq
#WomensHealth
$DARE CEO Sabrina Martucci Johnson attended the Forbes 30/50 Summit as a 2026 Forbes 50 Over 50 honoree.
Inspiring panels, including remarks from Hillary Clinton, reinforced the urgent need to address maternal mortality and advance women's health.
Thank you, Forbes!
@Forbes
Daré Bioscience Surpasses $43 Million in Non-Dilutive Grant Funding as Investigational Programmable Drug Delivery Platform Gains Momentum
https://t.co/SFTd4EwzI7
$DARE #WomensHealth#Biotech#HealthcareInnovation#PatientCare
We had the chance to meet Dr. Jill Biden at The Menopause Society Annual Meeting, where she delivered this year's keynote. As Chair of the Milken Institute Women's Health Network, Dr. Biden is a steady champion for investment in women's health research.
$DARE #WomensHealth
At the WME Women's Health Summit last week, Secretary Xavier Becerra and Biocom chair and President Sabrina Johnson connected with Assembly member Rebecca Bauer-kahan on the research gaps and policy decisions shaping women's care.
@wme @wmecommunity
$DARE #WomensHealth
Daré Bioscience to Showcase Its Investigational Programmable Device, DARE-IDDS, at PODD 2026: One Device, Designed to Deliver 100+ Doses and to be Controlled Wirelessly
https://t.co/l1zChLPOTA
$DARE #WomensHealth#Biotech#HealthcareInnovation#PatientCare
The White House issued an Executive Order on Advancing Women's Health to Improve Outcomes in All Phases of Life, including a new Women's Health Division at the National Institutes of Health.
Read more: https://t.co/3o8DMbcdRL
$DARE #WomensHealth
CEO Sabrina Martucci Johnson shares insights into $DARE's growing commercial portfolio, clinical pipeline and strategic priorities, including the Company's transition to a commercial-stage women's health company in their new CEO Corner Series.
🔗: https://t.co/icKslfNfyl
Daré Bioscience Launches "CEO Corner" Video Series to Highlight the Company's Pipeline of Women's Health Innovations, Corporate Strategy and Opportunities
https://t.co/1O8mpCcCQ8
$DARE #WomensHealth#Biotech#HealthcareInnovation#PatientCare
Daré Bioscience to Present Phase 1 Sildenafil Cream Data at Sexual Medicine Society of North America (SMSNA) Annual Fall Scientific Meeting
https://t.co/9I2lUOpWOM
$DARE #WomensHealth#Biotech#HealthcareInnovation#PatientCare
Daré Bioscience Announces New U.S. Patent Strengthening DARE-HPV Program as a Potential First FDA-Approved Pharmacologic Treatment for HPV Infection
https://t.co/zAGDD0xrUq
$DARE #WomensHealth#Biotech#HealthcareInnovation#PatientCare
Daré Bioscience Announces Peer-Reviewed Publication of Phase 1 Sildenafil Cream Study in Men Demonstrating Substantially Lower Systemic Exposure Versus Oral Sildenafil
https://t.co/Pjkd1rl6KQ
$DARE #WomensHealth#Biotech#HealthcareInnovation#PatientCare